We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pharmanet Development Grp (MM) | NASDAQ:PDGI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.04 | 0 | 01:00:00 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Expires: February 28, 2011 Estimated average burden hours per response... 0.5 |
|
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person
*
Sheldrick Robin Cashen |
2. Issuer Name
and
Ticker or Trading Symbol
PharmaNet Development Group Inc [ PDGI ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) Senior VP, Human Resources |
C/O PHARMANET DEVELOPMENT GROUP, INC., 504 CARNEGIE CENTER |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
PRINCETON, NJ 08540 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock, Par Value $.001 (1) | 3/20/2009 | U | 16612 (1) | A | $5.00 | 0 (1) | D |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
OPTIONS TO PURCHASE COMMON STOCK, PAR VALUE $.001 | $40.39 | 3/20/2009 | D | 2626 | (2) | (2) | COMMON STOCK, PAR VALUE $.001 | 2626 (2) | $0 | 0 | D | ||||
OPTIONS TO PURCHASE COMMON STOCK, PAR VALUE $.001 | $13.86 | 3/20/2009 | D | 3571 | (2) | (2) | COMMON STOCK, PAR VALUE $.001 | 3571 (2) | $0 | 0 | D | ||||
OPTIONS TO PURCHASE COMMON STOCK, PAR VALUE $.001 | $26.91 | 3/20/2009 | D | 1218 | (2) | (2) | COMMON STOCK, PAR VALUE $.001 | 1218 (2) | $0 | 0 | D | ||||
OPTIONS TO PURCHASE COMMON STOCK, PAR VALUE $.001 | $29.47 | 3/20/2009 | D | 1254 | (2) | (2) | COMMON STOCK, PAR VALUE $.001 | 1254 (2) | $0 | 0 | D |
Explanation of Responses: | |
( 1) | Of such amount, 4,300 shares automatically vested and were paid for in connection with the change in control which occurred upon the acceptance of shares pursuant to the tender offer (the "Offer") which was launched in connection with the Agreement and Plan of Merger dated February 3, 2009 by and among JLL PharmaNet Holdings, LLC ("Parent"), PDGI Acquisition Corp. ("Purchaser") and PharmaNet ("PharmaNet"). On March 20, 2009, all shares which were tendered by the filing person in connection with the Offer, were accepted by the Purchaser. Any shares which were not tendered by the filing person will be cashed out at the closing of the Merger. |
( 2) | Such options were canceled in connection with the Merger in exchange for the right to receive the difference between the merger consideration of $5.00 per share and the options exercise price. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Sheldrick Robin Cashen
C/O PHARMANET DEVELOPMENT GROUP, INC. 504 CARNEGIE CENTER PRINCETON, NJ 08540 |
|
|
Senior VP, Human Resources |
|
Signatures
|
||
/s/ Robin Sheldrick | 3/24/2009 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Pharmanet Development Grp (MM) Chart |
1 Month Pharmanet Development Grp (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions